Acute myeloid leukemia (AML) can be a difficult disease to cure. However, advances in AML treatment have resulted in improved remission (an absence of signs and symptoms) and cure rates.
Treatment outcomes can be broken down into four categories. The table below describes the difference between each category.
|Minimal residual disease||No AML cells are detected in bone marrow using standard tests. But more sensitive tests, such as flow cytometry, or very sensitive tests, such as polymerase chain reaction (PCR), detect remaining AML cells in the marrow.|
|Complete molecular remission||No evidence of AML cells in the marrow when using very sensitive tests such as PCR.|
|Remission (complete remission)||
No evidence of disease after treatment, based on:
|*A finding of 1 percent to 5 percent blast cells in the marrow doesn't indicate that a patient has minimal residual disease. This percentage of blast cells can be found in people who don't have leukemia.|
For survival statistics, click here.